International Journal of Clinical Research
International Journal of Clinical Research. 2023; 7: (2) ; 10.12208/j.ijcr.20230088 .
总浏览量: 353
北京市门头沟区龙泉医院 北京
*通讯作者： 沈杨,单位：北京市门头沟区龙泉医院 北京；
目的 研究对维持期精神分裂症患者应用低有效量利培酮联合奥氮平治疗时所展现的实施效果进行评价，探讨精神分裂症维持期的药物治疗方案的选择。方法 回顾性分析2018年1月-2022年10月期间在我院诊断并开展治疗的维持期精神分裂症患者，共计88例，根据患者用药情况应用利培酮联合奥氮平治疗者编为研究组，单一利培酮药物治疗者编为对照组。同时对两组患者的PANSS评分、临床疗效、血常规指标及不良反应发生率等进行统计分析。结果 本研究中研究组患者的临床总有效率更高，PANSS量表阴性症状评分和总分显著低于对照组。药物不良反应的发生率显著低于对照组（P＜0.05）。两组血液学变化无统计学差异。结论 对维持期精神分裂症患者应用低有效量利培酮联合奥氮平治疗对改善患者的治疗效果有良好作用，有效改善患者的阴性症状，减少不良反应的发生，有利于患者的康复。
Objective: To evaluate the effect of loweffective dose risperidone combined with olanzapine in the maintenance period of schizophrenia, and to explore the choice of drug treatment in the maintenance period of schizophrenia. Methods: A total of 88 patients with maintenance schizophrenia diagnosed and treated in our hospital from January 2018 to October 2022 were retrospectively analyzed. According to the drug use of patients, patients receiving risperidone combined with olanzapine were assigned as the study group, while patients receiving risperidone alone were assigned as the control group. At the same time, PANSS score, clinical efficacy, blood routine indexes and the incidence of adverse reactions were statistically analyzed. Results: In this study, the total clinical effective rate of the study group was higher, and the PANSS negative symptom score and total score were significantly lower than those of the control group. The incidence of ADR was significantly lower than that of control group (P < 0.05). There was no significant difference in hematology between the two groups. Conclusion : Low dose risperidone combined with olanzapine has a good effect on improving the therapeutic effect of patients with maintenance schizophrenia, effectively improving the negative symptoms of patients, reducing the occurrence of adverse reactions, and is conducive to the rehabilitation of patients.
[1] Winship IR, Dursun SM, Baker GB, etal. An Overview of Animal Models Related to Schizophrenia [J]. Can J Psychiatry. 2019, 64(1):5-17.
[2] Loots E, Goossens E, Vanwesemael T, et al. Interventions to Improve Medication Adherence in Patients with Schizophrenia or Bipolar Disorders: A Systematic Review and Meta-Analysis [J]. Int J Environ Res Public Health. 2021, 18(19):10213.
[3] Rhee TG, Rosenheck RA. Does improvement in symptoms and quality of life in chronic schizophrenia reduce family caregiver burden [J]? Psychiatry Res. 2019, 271:402-404.
[4] Kimura H, Kanahara N, Iyo M. Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity [J]. Behav Brain Res. 2021, 403:113126.
[5] Yang L, Qi X. Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function [J]. Pak J Med Sci. 2021, 37(3):646-650.
[6] Yoshimura Y, Takeda T, Kishi Y, et al. Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study [J]. Int Clin Psychopharmacol. 2018, 33(3):147-154.
[7] Barry CL, McGinty EE, Pescosolido BA, et al. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness [J]. Psychiatr Serv. 2014, 65(10):1269-72.
[8] Chopko TC, Lindsley CW. Classics in Chemical Neuroscience: Risperidone [J]. ACS ChemNeurosci. 2018, 9(7):1520-1529.
[9] Kahn René S.,Silverman Bernard L., Di Petrillo Lauren, GrahamChristine,JiangYing,YinJiani,SimmonsAdam,BhupathiVasudev,YuBei,YagodaSergey,HopkinsonCraig,McDonnellDavid.A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension [J]. Schizophrenia Research. 2021: 32-38.
[10] Correll Christoph U, Newcomer John W, Silverman Bernard, Di Petrillo Lauren, Graham Christine, Jiang Ying, Du Yang chun, Simmons Adam, Hopkinson Craig, Mc Donnell David, Kahn René S.Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.The American journal of psychiatry .[J] .2020,(12):112-119.
[11] Morrison AP, Pyle M, Byrne R, et al. Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT [J]. Health Technol Assess. 2021, 25(4):1-124.
[12] Güneş M, Camkurt MA, Bulut M, et al. Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment [J]. Clin Psychopharmacol Neurosci. 2016, 14(4):345-350.
[13] Lähteenvuo M, Tiihonen J. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations [J]. Drugs. 2021, 81(11):1273-1284.
[14] Greenwood J, Acharya RB, Marcellus V, et al. Lumateperone: A Novel Antipsychotic for Schizophrenia [J]. Ann Pharmacother. 2021, 55(1):98-104.
[15] Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis [J]. Lancet. 2022, 399(10327):824-836.